Home » Newsletters » BioWorld Science

BioWorld Science

April 25, 2006

View Archived Issues

Results of Alltracel's statin and bioactive combination preclinical studies

Pathogenics licenses N-chlorotaurine rights to Acuity

Karo Bio to receive milestone payment from Wyeth for LXR modulator project

New trial studies WinRho SDF in HCV patients

MedImmune and Elusys collaborate on new therapies targeting infectious disease

Novel Syk inhibitor for RA

New class of antitumor agents that degrade JAK2, Bcr-Abl and c-Myc

Stabilized brain volumes seen in phenserine-treated Alzheimer's patients

Gen-Probe seeks approval of Procleix Tigris system for WNV screening

ILY-101 completes phase I trial for hyperphosphatemia

Bionomics nominates first drug candidate

Enrollment complete in COSTAR II stent study

Phase IIb program begins for collaborative LABA compound

Gene Logic and Organon sign drug repositioning agreement

SkyePharma and Endo agreement to terminate Propofol IDD-DTM agreement

HCV levels reduced in nonresponders receiving HCV-I.E.T.

Histone deacetylase (HDAC) inhibition and neuroprotection

Snapshots on targets for Alzheimer's disease

New data on novel Src inhibitor from Ariad

Humatrope approved for growth hormone deficiency in Japan

Detrusitol receives Japanese approval for overactive bladder

Novel analgesic agents disclosed in recent patent literature

Novel agents for asthma and other respiratory disorders patented

Novel diagnostic agents divulged in recent patents

UNBS-3157: a novel amonafide analogue with an improved efficacy and safety profile

Novel Bcr-Abl inhibitor active against imatinib-resistant mutants

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...